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Abstract
Background: Smoking is a risk factor for postoperative pulmonary complications (PPC) following non-small cell
lung cancer (NSCLC) surgery. The optimal timing for preoperative smoking cessation has not been identified. Our
study aimed to observe the impact of preoperative smoking cessation on PPC incidence and other postoperative
outcomes including long-term survival.
Methods: A prospective study included consecutive patients following resection for NSCLC in a regional thoracic
centre over a 4-year period (2010–2014). Patients were stratified according to self-reported preoperative smoking
status. The primary endpoint was PPC incidence, which was assessed from postoperative day one onwards using
the Melbourne Group Scale. Secondary endpoints included short-term outcomes (hospital length of stay [LOS],
intensive therapy unit [ITU] admission, 30-day hospital readmission rate) and long-term survival.
Results: Four hundred and sixty-two patients included 111 (24%) current smokers, 55 (12%) ex-smokers <6 weeks, 245
(53%) ex-smokers ≥6 weeks and 51 (11%) never smokers. PPC occurred in 60 (13%) patients in total. Compared to never
smokers, current smokers had a higher frequency of PPC (22% vs. 2%, p = 0.004), higher frequency of ITU admission (14%
vs. 0%; p = 0.001) and a longer median (IQR) hospital LOS (6 [5] vs. 5 [2]; p = 0.001). In the ex-smokers there was a trend
for a lower frequency of PPC (<6 weeks, 10.9% vs. ≥6 weeks, 11.8%) and ITU admission (<6 weeks, 5.5% vs. ≥6 weeks, 4.
5%), but there was no difference between the <6 weeks or ≥6 weeks ex-smoking groups prior to surgery. There was no
significant difference in long-term survival found between the groups of differing smoking status (median follow-up 29.8
months, 95%CI 28.4–31.1).
Conclusion: Current smokers have higher postoperative morbidity; this risk reduces following smoking cessation but 6
weeks does not appear to identify a time-point where differences in outcomes are noted.
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Background
Non-small-cell lung cancer (NSCLC) represents ap-
proximately 85% of all lung cancer cases. In early-stages,
surgery remains the corner stone of treatment, but is
complicated by a high risk of developing a postoperative
pulmonary complication (PPC), of which atelectasis and
pneumonia are most common. Developing a PPC has
been shown to increase in short-term complications in-
cluding increased hospital mortality (0.5% to 12%), ITU
admission rate (1.5% to 26%) and hospital length of stay
(LOS) (5 to 14 days) [1]. Patients who develop a PPC
also have a poorer long-term outcome with a 6-month
reduction in mean overall survival [2]. We have previ-
ously demonstrated that smoking is the strongest inde-
pendent risk factor for developing a PPC after thoracic
surgery [1–2]. Furthermore, smoking has been shown to
have a negative impact on long-term overall survival and
disease progression in lung cancer patients following
curative-intent surgery [3].
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Risk modification is via preoperative smoking cessa-
tion. Few studies have suggested that smoking abstin-
ence of at least 4 weeks may be necessary for patients
undergoing thoracic surgery in order to reduce the inci-
dence of PPC and hospital mortality [4, 5]. Despite this,
an optimal duration of preoperative smoking cessation
has not been identified. Many studies addressing this
question are retrospective in nature with small sample
sizes, the definition and criteria of PPC varies between
studies and there is a paucity of published studies dem-
onstrating the effects of preoperative smoking cessation
on long-term survival.
To address these issues, the primary aim of this study
was to prospectively observe the timing of preoperative
smoking cessation on PPC incidence following curative-
intent lung cancer surgery. The secondary aim of this
study was to follow up these patients to ascertain if an
optimal interval of preoperative smoking cessation is
identifiable to improve the short-term postoperative out-
come and long-term survival.
Methods
Patient selection
This prospective observational study included all pa-
tients who underwent curative-intent lung resection for
NSCLC via open thoracotomy or video-assisted thora-
coscopic surgery (VATS) in a large UK thoracic centre
between April 2010 and April 2014. The study received
ethics approval by the National Research Ethics Service
Committee West Midlands, Edgbaston. Decisions re-
garding patient selection and operability were informed
by the British Thoracic Society guidelines [6]. Preopera-
tive smoking status was categorised into current
smokers who continued up to the date of surgery; ex-
smokers who stopped smoking <6 weeks prior to sur-
gery, ex-smokers who stopped smoking ≥6 weeks prior
to surgery, and never smokers. Six weeks was chosen as
the reporting period as previous evidence suggested
that preoperative smoking cessation interventions
might be more beneficial when offered within this time-
frame, rather than immediately before surgery [7].
Smoking data was collected by patients self-reporting
to the specialist thoracic research team (including
nurses and physicians) at the preoperative assessment
and the hospital admission using a paper based case re-
port form, which was then uploaded onto the electronic
database.
All operations were performed with single lung venti-
lation under general anaesthesia. Patients were subse-
quently scheduled for extubation in the operating room
and postoperatively managed in a thoracic high-
dependency unit (HDU) (level 2) and specialist ward
unless complications required their admission to the
ITU. The choice of postoperative analgesia was agreed
between the anaesthetist and patient. From postopera-
tive day one, all patients received daily physiotherapy
comprising of deep breathing exercises, incentive spir-
ometry, supported coughing and mobilisation.
All patients included in the study had a confirmed
pathologically staged diagnosis of NSCLC (TNM 7th
edition). Baseline data included demographics, body
mass index (BMI), percentage predicted forced expira-
tory volume in one second (FEV1), American Society of
Anaethesiologists (ASA) score and subjective preopera-
tive physical activity level. Comorbidities including car-
diovascular disease COPD diagnosis were both defined
by the referring physician, with COPD severity staged
according to percentage predicted FEV1.
Primary endpoint
The Melbourne Group Scale (MGS) is a standardised
scoring system previously validated by our group to de-
fine the presence/absence of a PPC [1]. The MGS
defines PPC when patients present with four or more
of the following eight factors: chest x-ray (CXR) find-
ings of atelectasis or consolidation, raised white blood
cell count (WBC) (>11.29/l) or administration of antibi-
otics (in addition to prophylactic antibiotics),
temperature >38 °C; signs of infection on sputum
microbiology, purulent sputum differing from pre-
operative status, oxygen saturations <90% on room air,
physician diagnosis of chest infection/pneumonia, and
prolonged HDU stay or readmission to HDU or ITU
for respiratory complications. The MGS was used daily
from postoperative day one onwards by senior physio-
therapists who were performing their routine respira-
tory assessments. CXR results and physician diagnoses
of chest infection/pneumonia were confirmed by a
senior thoracic surgeon.
Secondary endpoints
Postoperative data included hospital LOS, ITU LOS,
ITU admission frequency and 30-day hospital readmis-
sion rates (secondary to surgical or pulmonary complica-
tions). All patients were followed up during the study
period for overall survival; defined as the time from date
of surgery to the date of death or censored at the last
date of confirmed living status. Cause of death was ob-
tained from the death certificate and hospital records.
Deaths were classified as a postoperative complication
for those who died within the initial hospital admission
or within 30-days of surgery, cancer related for patients
who died of disease progression or recurrence, non-
cancer related from patients who died of other causes,
or cause of death unknown where records were not
available.
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Statistical analysis
Results are expressed as mean (95%CI) or median (IQR)
for continuous variables depending on normality of data
and as a percentage for categorical variables. Univariate
analysis of risk factors using Pearson’s chi-square test or
Fisher’s exact test where appropriate for categorical vari-
ables, and Kruskal-Wallis test or ANOVA for continuous
variables were performed following the assessment of
normality of data.
Significant predictors of survival were identified using
Proportional Cox regression modeling. Covariates were
assessed for validity of proportional hazard assumption
prior to inclusion in the model. Standardized score
process and cumulative martingale residuals plots were
generated. The following covariates were well specified
and met the proportional hazard assumption: stage,
age, PPC, total LOS, ITU LOS, VATS surgery, hyper-
tension, diabetes, ischaemic heart disease, COPD,
FEV1 % predicted, sex, type of analgesia, preoperative
physical activity level and smoking status. The statis-
tical significant covariates were identified following a
backward elimination process. The level of significance
was set at 0.05. Predictive survival curves adjusted for
the different smoking status categories were generated
based on the final Cox proportional hazards model at
different levels of the predictor variables. All analyses
were performed using the SAS statistical package ver-
sion 9.3 (SAS Institute, Inc, Carry NC) and IBM SPSS
version 20.0.
Results
Study population
There were 462 patients with NSCLC who underwent
pulmonary resection during the study period of which
277 (60%) were male. The mean ± SD age of the group
was 68.8 ± 8.5 years. The mean predicted FEV1 was 79.2
± 20.4%, mean BMI was 26.8 ± 8.9 kg/m2, 237 (51.3%)
had an ASA score ≥3 and 136 (29.4%) had COPD. There
were 111 (24%) current smokers, 55 (12%) ex-smokers
<6 weeks, 245 (53%) ex-smokers ≥6 weeks, and 51 (11%)
never smokers.
The most frequent procedures were lobectomy (n = 361,
78.1%), followed by wedge or segmentectomy (n = 61,
13.2%), pneumonectomy (n = 32, 6.9%), sleeve resections
(n = 6, 1.3%) and chest wall resection/reconstruction
(n = 2, 0.4%). VATS approach was used in 39 patients
(8.4%). Patients were NSCLC staging of I (n = 229,
50%), II (n = 147, 32%), IIIA (76, 16%) and IIIB (n = 6, 1%).
Age, FEV1% predicted and BMI were all significantly
lower (p < 0.05) in current smokers than never smokers.
There were significantly more males and patients with
COPD diagnosis in the current smoking group (p < 0.05,
Table 1); though there were no significant differences in
the severity of COPD between groups. Cancer staging,
preoperative physical activity level, ASA score and diag-
nosis of cardiovascular disease were not significantly
associated with smoking.
PPC incidence
PPC was present in 60 patients (13%); the most com-
mon positive factors to trigger a score of 4 were raised
WBC (n = 54, 11.7%), purulent sputum (n = 48, 10.4%),
CXR findings (n = 48, 10.4%), and reduced oxygen satu-
rations (n = 48, 10.4%). Compared to never smokers,
current smokers had a higher frequency of PPC (22%
vs. 2%, p = 0.004) (Table 2). Compared to current
smokers, in the ex-smoking groups there was a trend
for a lower frequency of PPC (<6 weeks, 10.9% vs. ≥6
weeks, 11.8%) but there was no significant differences
between ex-smoking groups, or when compared to
current and never smokers.
Short-term outcome
Compared to never smokers, current smokers had a
higher frequency of ITU admission (14% vs. 0%; p = 0.001)
as well as longer median (IQR) hospital LOS (days) (6 [5]
vs. 5 [2]; p = 0.001). Compared to current smokers, in the
ex-smoking groups there was a trend for a lower fre-
quency of ITU admission (<6 weeks, 5.5% vs. ≥6 weeks,
4.5%). but there was no significant differences between ex-
smoking groups, or when compared to current and never
smokers. Patients who stopped smoking ≥6 weeks prior to
surgery were found to have a significantly shorter ITU
median (IQR) LOS (days) compared to current smokers
(3 [2] vs. 4 [10]; p = 0.002). There was no significant differ-
ence in 30-day hospital readmission rates between any of
the groups. There were no significant differences in the
30-day mortality, 90-day mortality or causes of death
(cancer or non-cancer related) between any of the groups.
Long-term survival
When assessing for survival, the mean follow up time
for all patients was 29.8 months (95%CI 28.4–31.1).
After excluding early postoperative deaths, Cox regres-
sion analysis showed significant independent risk factors
for late deaths following thoracic surgery to be PPC de-
velopment, age, cancer staging and hospital LOS
(Table 3). Smoking variable was not a significant pre-
dictor for late deaths (p > 0.05) but after adjusting for
the significant covariates, the adjusted survival curves
for the never smokers were clearly above the survival
curves for the rest of smoking categories (Fig. 1).
Discussion
This study demonstrates that patients who continue to
smoke until the date of curative-intent lung cancer sur-
gery have a higher postoperative morbidity, including
higher frequency of PPC, longer hospital LOS, and a
Lugg et al. Journal of Cardiothoracic Surgery  (2017) 12:52 Page 3 of 8
higher frequency of ITU admission. In ex-smokers there
was trend for reduced frequency of PPC and ITU admis-
sion compared to current smokers, but there was no sig-
nificant difference in observed outcome between
patients who quit smoking less <6 weeks versus ≥6
weeks prior to surgery. We found no significant differ-
ences in early mortality or long-term survival between
any of the groups within our follow up period.
Our study demonstrated that the incidence of PPC in
current smokers is 22%, which is greater than 10 times
that of never smokers and twice that of ex-smokers.
Comparing this observed incidence with results from
other studies is challenging because of the differences
in the definition of PPC, which may extend to include
potentially more severe yet less frequent complications
such as pulmonary embolism, prolonged air leaks and
bronchopleural fistulas [8]. Despite this, the frequency
of PPC in smokers using the MGS is within the wide
range of pulmonary events reported in other studies
(6.9–43.2%) [5, 9]. Our finding of PPC to be higher in
Table 1 Results of univariate analysis to determine factors associated with smoking status
Current smokers Ex-smokers
<6 weeks
Ex-smokers
≥6 weeks
Never smokers p-value
(n = 111) (n = 55) (n = 245) (n = 51)
Mean (95%CI) age (years) 67 (65–68.3)f 68 (65.6–9.9)e,f 70 (68.8–70.8)e 72 (67.2–72.8)e,f 0.006a
Median (IQR) BMI (kg/m2) 24.1 (6.3)f 24 (7.5)e 26.9 (5.4)e,f 26 (6.4)e,f <0.001b
Mean (95%CI) FEV1% predicted 72 (68.6–75.7)
g 78 (73.5–81.8)f,g 79 (76.6–81.8)e,f 94 (87.4–100.5)e <0.001a
COPD 50.4% (n = 56)g 20.0% (n = 11)f,g 26.9% (n = 66)e,f 5.9% (n = 3)e <0.001c
COPD Severity (FEV1% predicted) Mild (≥80) 18.9% (n = 21) 3.6% (n = 2) 6.5% (n = 16) 2% (n = 1) 0.358
d
Moderate (≥50 to <80) 23.4% (n = 26) 16.4% (n = 9) 15.5% (n = 38) 3.9% (n = 2)
Severe (≥30 to <50) 8.1% (n = 9) 0% 4.5% (n = 11) 0%
Male sex 63.9% (n = 71)f 60.0% (n = 33)e,f 63.2% (n = 155)f 35.2% (n = 18)e 0.002c
Ischaemic heart disease 14.4% (n = 16) 18.1% (n = 10) 15.1% (n = 37) 7.8% (n = 4) 0.476c
Diabetes 12.6% (n = 14) 5.5% (n = 3) 13.1% (n = 32) 11.7% (n = 6) 0.503d
Hypertension 42.3% (n = 47) 41.8% (n = 23) 45.3% (n = 111) 52.9% (n = 27) 0.604c
ASA score ≥3 58.5% (n = 65) 52.7% (n = 29) 49.8% (n = 122) 41.2% (n = 21) 0.195c
Preoperative activity level <400 m 29.4% (n = 32/109) 25% (n = 13/52) 29.7% (n = 71/239) 21.6% (n = 11/51) 0.634c
Staging I 54.1% (n = 60) 47.3% (n = 26) 48.2% (n = 118) 49.0% (n = 25) 0.36 d
II 29.7% (n = 33) 32.7% (n = 18) 34.7% (n = 85) 21.6% (n = 11)
IIIA 14.4% (n = 16) 18.2% (n = 10) 15.9% (n = 39 21.6% (n = 11)
IIIB 0.90% (n = 1) 0% 0.41% (n = 1) 3.9% (n = 2)
VATS No 91.9% (n = 102) 85.5% (n = 47) 92.7% (n = 227) 92.2% (n = 47) 0.396d
Yes 8.1% (n = 9) 14.5% (n = 8) 7.3% (n = 18) 7.8% (n = 4)
Surgery Lobectomy 81.1% (n = 90) 78.2% (n = 43) 77.6% (n = 190) 74.5% (n = 38) 0.592d
Subsegmectomy/wedge 10.8% (n = 12) 9.1% (n = 5) 14.3% (n = 35) 17.6% (n = 9)
Pneumonectomy 5.4% (n = 6) 10.9% (n = 6) 6.5% (n = 16) 7.8% (n = 4)
Sleeve 1.8% (n = 2) 0% 1.6% (n = 4) 0%
Chest wall 0.9% (n = 1) 1.8% (n = 1) 0% 0%
Analgesia Epidural 40.5% (n = 45) 29.0% (n = 16) 37.1% (n = 91) 43.1% (n = 22) 0.217d
Intrathecal morphine 23.4% (n = 26) 36.4% (n = 20) 21.6% (n = 53) 21.6% (n = 11)
Morphine infusion 11.7% (n = 13) 10.9% (n = 6) 8.6% (n = 21) 5.9% (n = 3)
PCA 5.4% (n = 6) 7.3% (n = 4) 5.3% (n = 13) 5.9% (n = 3)
Paravertebral 18.9% (n = 21) 12.7% (n = 7) 26.5% (n = 65) 23.5% (n = 12)
Other 0% 3.6% (n = 2) 0.8% (n = 2) 0%
BMI body mass index, FEV1 forced expiratory volume in one second, COPD chronic obstructive pulmonary disease, ASA American Society of Anaethesiologists,
VATS Video-assisted thoracoscopic surgery, PCA patient controlled analgesia.a ANOVA with Bonferroni post-hoc analysis;b Kruskal-Wallis test with Dunn Bonferroni
post-hoc multiple comparison test;c Chi-sqaure test with Bonferroni post-hoc analysis;d Fisher’s Exact test with Bonferroni post-hoc analysis. When overall p-value
is less than 0.05; each subscript letter(e-g) denotes a subset of smoking category whose column proportion does not differ significantly from each other (Bonferroni
post-hoc multiple comparison test)
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current versus never smokers is also supported by other
studies [5, 10].
Despite the observed trend, our study showed no sig-
nificant difference in PPC frequency between ex-
smokers and current/never smokers. Other studies have
found no significant difference in ex-smokers and
current/never smokers which is most likely due to much
smaller study sample sizes [9], and/or the exclusion of a
never smoking control group [11, 12]. In a general thor-
acic surgery cohort, we recently demonstrated that com-
pared to never smokers, ex-smokers were more than
twice as likely to develop a PPC [2]. However, the timing
of smoking cessation prior to surgery, and the subse-
quent effect of postoperative outcome was not
investigated.
In our prospective cohort, using 6 weeks as a cut off,
we were unable to find an optimum duration of pre-
operative smoking cessation to reduce PPC incidence.
Despite this, our study has demonstrated that stopping
smoking 6 weeks prior to surgery seems to reduce, and
not increase PPCs compared to current smokers. Inter-
estingly, the study by Nakagawa et al (n = 288) [4]
found the incidence of PPCs among ex-smokers (2–4
weeks prior to surgery) was 53.8%, whilst in current
smokers was 43.6%, which were both significantly
higher when compared to the never-smokers (23.9%;
p < 0.05). However, this study is limited by the retro-
spective nature of data collection. As defined by Rus-
sell Standard [13], the study found that at least 4
weeks of smoking abstinence was needed for a
marked reduction in PPC (53.8% to 34.7%), whilst the
incidence of PPC in patients who had a smoke-free
period of 9–12 weeks or longer approached the same
incidence as those in the never-smoked group. A
large prospective review of the General Thoracic
Surgery Database from the United States (n = 7990)
found that the risk of PPCs following primary resec-
tion for lung cancer steadily declined with longer in-
tervals of smoking cessation (4 days - 1 month, 1–12
months, >12 months) [5]. However the differences
were not significant enough between the groups to
recommend optimal interval of smoking cessation.
One critique of this study is that the incidence of
PPC was low (6.9% in smokers) as only major pul-
monary events were reported, suggesting minor yet
more frequent PPCs may have been missed.
Smoking had no direct effect on postoperative mortal-
ity or long-term survival during in our study. Neverthe-
less, the adjusted survival curves for never smokers were
Table 2 Morbidity and mortality in patients stratified by smoking status
Current smokers Ex-smokers
<6 weeks
Ex-smokers
≥6 weeks
Never smokers p-value
(n = 111) (n = 55) (n = 245) (n = 51)
PPC Frequency 21.6% (n = 24)d 10.9% (n = 6)c,d 11.8% (n = 29)c,d 2.0% (n = 1)c 0.004a
ITU admission 14.4% (n = 16)d 5.5% (n = 3)c,d 4.5% (n = 11)c,d 0%c 0.001b
Median (IQR) LOS (days) 6 (5)d 5 (3)c,d 6 (4)c,d 5 (2)c 0.001f
Median (IQR) ITU LOS (days) 4 (10) (n = 16)e 2 ( * ) (n = 3)c,d,e 3 (2) (n = 11)c,d 0 (0) (n = 0)c 0.002f
30-day hospital readmissions 13.6% (n = 15) 14.8% (n = 8) 15.1% (n = 36) 7.8% (n = 4) 0.793a
Mortality Total 30.6% (n = 34) 32.7% (n = 18) 30.2% (n = 74) 23.5% (n = 12) 0.744a
30-day 1.8% (n = 2) 0% 2.4% (n = 6) 2.0% (n = 1) 0.874b
90-day 5.4% (n = 6) 1.8% (n = 1) 3.2% (n = 8) 5.9% (n = 3) 0.575b
Cause of death Early Postoperative Complications 2.7% (n = 3) 3.6% (n = 2) 2.9% (n = 7) 2.0% (n = 1) 0.970b
Cancer related 18.9% (n = 21) 20.0% (n = 11) 20.4% (n = 50) 17.6% (n = 9) 0.968a
Non-cancer related 6.3% (n = 7) 5.5% (n = 3) 6.9% (n = 17) 1.9% (n = 1) 0.768b
Uncertain 2.7% (n = 3) 3.6% (n = 2) 0% 1.9% (n = 1) 0.015b
Mean (95%CI) overall survival (months) excluding early postoperative
complications
42 (42–45) 42 (38–47) 43 (40–46) 46 (41–50) 0.778g
PPC postoperative pulmonary complication, ITU intensive therapy unit, LOS length of stay.a Chi-square test with Bonferroni post-hoc analysis;b Fisher’s Exact test
with Bonferroni post-hoc analysis. When overall p-value is less than 0.05; each subscript letter(c-e) denotes a subset of smoking category whose column proportion
does not differ significantly from each other (Bonferroni post-hoc multiple comparison test);f kruskal-Wallis test with Dunn-Bonferroni post-hoc multiple compari-
son test;g ANOVA with Bonferroni post-hoc analysis.;h interquartile range not applicable due to number of patients
Table 3 Independent risk factors for late deaths
Variables Parameter estimate SE p-value HR 95%CI
Stage (II vs. I) 1.11 0.22 <0.0001 3.03 1.97–4.71
Stage (IIIA vs. I) 1.35 0.25 <0.0001 3.87 2.39–6.28
Stage (IIIB vs. I) 1.88 0.61 0.0019 6.54 1.57–18.33
Age 0.03 0.01 0.0115 1.03 1.01–1.05
PPC 0.53 0.27 0.0469 1.71 0.98–2.82
LOS 0.03 0.01 0.0324 1.03 1.01–1.05
PPC postoperative pulmonary complication, LOS length of stay
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clearly above those of the other smoking categories
especially after the first 12 months of follow up, suggest-
ing a likely more favorable outcome even though this
did not reach statistical significance. This may be in part
due to the short follow up period or the smoking habits
of patients after surgery; some may stop whilst others
may restart. Other studies have shown increased mortal-
ity in smokers compared to never smokers, but no sig-
nificant difference amongst the current and ex-smoking
groups [5, 13]. The deleterious effect of continued smok-
ing on long-term survival after being diagnosed with
lung cancer is increasingly evident [14], but few papers
have looked into the effect of preoperative smoking ces-
sation on long-term survival in lung cancer patients
undergoing curative-intent surgery. A multicenter review
of 169 patients undergoing NSCLC resection found that
current smokers had a reduced 5-year survival in com-
parison to never smokers (72% vs. 91%, p = 0.02), and
that stopping smoking a year prior to cancer diagnosis
had no significant difference in long-term survival [9].
Interestingly, although smoking was not an independent
risk factor for late-deaths in our study, PPC develop-
ment and LOS were independent risk factors for late-
deaths, both of which were significantly increased in the
current smokers.
We found that lower FEV1% predicted, BMI and
COPD diagnosis were associated with current smoking
on univariate analysis. Other investigators have found
that the prevalence of low and normal BMI was greater
among patients who are active smokers; those under-
weight patients had a greater risk-adjusted LOS com-
pared to normal weight patients [15]. We have
previously investigated the risk factors for developing a
PPC, and although lower preoperative FEV1% predicted
and COPD diagnosis are associated with PPC on univar-
iate analysis, only COPD diagnosis is regarded as an in-
dependent risk factor for PPC development or
multivariate analysis [1, 2]. Even in these models, current
smoking remains the strongest independent risk factor
for PPC development. Authors have found carbon mon-
oxide diffusion capacity (DLCO) to be associated with
PPC development [10]; however, DLCO was not in-
cluded in this study, as it was only performed in patients
with limited exercise tolerance so data are limited.
The observed effects of smoking and increasing fre-
quency of PPC could be explained by the suppressive ef-
fect of cigarette smoking on the innate immune system.
Smoking impairs the mucociliary escalator and the abil-
ity to remove foreign bodies/pathogens in the larger air-
ways. This normalises after 15 days following smoking
cessation implying that it is not the only etiological fac-
tor in PPC development [16]. Smoking seriously impairs
antimicrobial [17, 18] and proinflammatory [19] func-
tions of alveolar macrophages. Furthermore, there is a
compounding effect on anaesthesia and smoking on sup-
pression of intraoperative antimicrobial/phagocytic ac-
tivity in alveolar macrophages. Smoking cessation of 6
months was needed to normalise proinflammatory
a b c
d e f
Fig. 1 Predictive Survival curves with 95%CI for patients with different preoperative smoking status, excluding early postoperative deaths,
adjusted for the significant covariates from the Cox proportional hazards model (Table 3). Covariates set at: a) PPC 0, Stage I; b) PPC 1, Stage I; c)
PPC 1, Stage II; d) PPC 0, Stage IIA; e) PPC 0, Stage IIIB; f) PPC 1, Stage IIIB. Age and LOS were set at mean and median values respectively
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function whilst only 3 months was required to normalise
phagocytic function [20].
The question of whether a smoking cessation
programme in surgery affects postoperative outcomes
has been more recently reviewed [21]. Implementation
6–8 weeks prior to elective orthopedic surgery reduced
postoperative complications (18% vs. 52%, p = 0.0003)
[22], whilst implementation 2 weeks prior to colorectal
surgery made no difference [23]. Despite increasing
numbers of small RCTs suggesting intensive smoking
cessation treatments work in people with pulmonary dis-
eases such as lung cancer, many patients continue to
smoke [24]. In thoracic surgery, pulmonary rehabilita-
tion programmes have shown promise in increasing
smoking cessation, with a trend for fewer PPCs in the
intervention group [25]; however, RCTs are needed to
confirm efficacy.
Limitations
In this prospective study, the main limitation is the reli-
ance on self-reporting smoking status in preoperative
patients to ascertain smoking cessation, which could result
in recall bias and underestimate the real smoking habits of
patients. Use of biochemical confirmation by use of ex-
haled carbon monoxide testing and measuring cotinine
levels from urine, saliva or blood could be used in future
studies [26]. Furthermore, smoking cessation data was col-
lected as a categorical variable, and therefore additional
statistical analysis using ROC curve analysis could not be
performed to further inform on a cut-off for the duration
of smoking cessation needed to reduce PPC incidence. In
our study, there were a low number of VATS cases in our
prospective cohort (8.4%), and only 5.6% of patients with
stage 1 NSCLC underwent VATS resection. The data of
this study preceded the growth of VATS lobectomies in
NSCLC patients; the vast majority of lung resection over
this time frame was performed via open thoracotomy. This
low level of VATS resections could confound the results
and make them less generalisable considering that many
studies have demonstrated a higher postoperative pulmon-
ary complication (PPC) rate with open thoracotomy vs.
VATS resections [27, 28]. Therefore, further studies are
required to investigate the effects of smoking cessation on
PPC frequency in VATS verses open thoracotomy cases.
Conclusions
Our real-life study demonstrates that approximately 1 in
5 patients continue to smoke prior to curative-intent
surgery for NSCLC. Smoking cessation prior to surgery
reduces PPC incidence as well as other important
markers of postoperative morbidity, thus we recommend
that all patients should undergo formal smoking cessa-
tion as part of the routine work up. The optimum timing
for preoperative smoking cessation however is yet to be
defined. Further research into effective preoperative
smoking cessation programmes and their short-term and
long-term effects is urgently needed.
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